Trial Profile
A Clinical Trial to Qualify the Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Dalotuzumab (Primary) ; Ridaforolimus (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 28 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Nov 2011 Planned end date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.